Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held by ProKidney Corp. on May 28, 2026. The company is incorporated in Delaware and its Class A common stock trades on The Nasdaq Stock Market under the symbol PROK.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Election of Directors: Stockholders elected three nominees to the Board of Directors for three-year terms expiring in 2029.
- William F. Doyle: 196,164,585 votes For; 1,459,235 votes Withhold.
- Alan M. Lotvin, M.D.: 193,179,768 votes For; 4,444,052 votes Withhold.
- Brian J.G. Pereira: 197,002,580 votes For; 621,240 votes Withhold.
- Ratification of Auditors: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- For: 239,091,167
- Against: 729,165
- Abstain: 382,882
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Confirm the specific term expiration dates for the newly elected directors (stated as 2029).
- Review the full proxy statement for details on director qualifications and the rationale for the auditor ratification.